Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.

2022

Evens, Andrew M

Connors, Joseph M

Younes, Anas

Ansell, Stephen M

Kim, Won Seog

Radford, John

Feldman, Tatyana

Tuscano, Joseph

Savage, Kerry J

Oki, Yasuhiro

Grigg, Andrew P

Pocock, Christopher

Dlugosz-Danecka, Monika

Fenton, Keenan

Forero-Torres, Andres

Liu, Rachael

Jolin, Hina

Gautam, Ashish

Gallamini, Andrea

Hodgkin lymphoma

cancer

Journal Article

10.3324/haematol.2021.278438

Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma (cHL). We report results for older patients with cHL treated in the large phase III ECHELON-1 study of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Modified progression-free survival (PFS) per independent review facility (IRF) for older versus younger patients (aged ≥60 versus.

link

Haematologica 2022; 107(5): 1086-1094

Haematologica